Сурвивин и его роль в патогенезе злокачественных опухолей
Аннотация
В последние годы уделяется много внимания изучению роли сурвивина и других белков семейства ингибиторов апоптоза в процессах опухолевой трансформации и прогрессии. Сурвивин экспрессируется во время эмбриогенеза и практически отсутствует во всех дифференцированных клетках взрослого организма, однако его экспрессия возобновляется в опухолевых клетках различных типов. Были предприняты многочисленные попытки использования этого белка в качестве диагностического и прогностического онкомаркера, а также в качестве мишени противоопухолевой терапии. Совсем недавно появились сведения о возможном участии сурвивина непосредственно в процессе метастазирования, что делает вопрос его изучения еще более актуальным. В данном обзоре обобщены существующие на сегодняшний день представления о структуре, механизмах функционирования сурвивина и экспрессии данного гена в опухолях человека. Особое внимание уделено его значению при саркомах различного происхождения.
Об авторах
О. В. Ковалева
Российский онкологический научный центр им. Н.Н. Блохина РАМН
Россия
Россия
А. Н. Шнейдерман
Российский онкологический научный центр им. Н.Н. Блохина РАМН
Россия
Россия
Е. М. Чевкина
Российский онкологический научный центр им. Н.Н. Блохина РАМН
Россия
Россия
O. Kovaleva
N.N. Blokhin Russian Cancer Research Center Russian Academy of Medical Sciences
Россия
Россия
A. Shneyderman
N.N. Blokhin Russian Cancer Research Center Russian Academy of Medical Sciences
Россия
Россия
E. Tchevkina
N.N. Blokhin Russian Cancer Research Center Russian Academy of Medical Sciences
Россия
Россия
Список литературы
1. Ambrosini G., Adida С., Altieri D.C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nature Med. 1997, v. 3, p. 917-921.
2. Uren A.G., Coulson E.J., Vaux D.L. Conservation of baculovirus inhibitor of apoptosis repeat proteins (BIRPs) in viruses, nematodes, vertebrates and yeasts. Trends Biochem. Sci. 1998, v. 23, p. 159-162.
3. Schimmer A. (2004) Inhibitor of Apoptosis Proteins: Translating Basic Knowledge into Clinical Practice. Cancer. Research. 2004, v. 64, p. 7183-7190.
4. Altieri D.C. Survivin, cancer networks and pathway-directed drug discovery. Nat. Rev. Cancer. 2008, v. 8. p. 61-70.
5. Mahotka C., Wenzel M., Springer E. et al. Survivin- deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different anti-apoptotic properties. Cancer. Research. 1999, v. 59, p. 6097-6102.
6. Zhu N., Gu L., Findley H.W. et al. An alternatively spliced survivin variant is positively regulated by p53 and sensitizes leukemia cells to chemotherapy. Oncogene. 2004, v. 23, p. 7545-7551.
7. Vegran F., Boidot R., Oudin С. et al. Distinct expression of Survivin splice variants in breast carcinomas. Int. J. Oncol. 2005, v. 27 (4), p. 1151-1157.
8. Caldas H., Honsey L., Altura R. Survivin 2α: a novel Survivin splice variant expressed in human malignancies. Molecular. Cancer. 2005, v. 4 p. 11.
9. Span P., Tjan-Heijnen V., Heuvel J. et al. Do the Survivin (BIRC5) Splice Variants Modulate or Add to the Prognostic Value of Total Survivin in Breast Cancer? Clinical. Chemistry. 2006, v. 52, 9, p. 1693-1700.
10. Khan S., Aspe J.R., Asumen M.G. et al. Extracellular, cell-permeable survivin inhibits apoptosis while promoting proliferative and metastatic potential. British Journal of Cancer. 2009, v. 100, p. 1073-1086.
11. Dohi T., Beltrami E., Wall N.R. et al. Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. J. Clin. Invest. 2004, v. 114, p. 1117-1127.
12. Ghosh J.C., Dohi T., Kang B.H., Altieri D.C. Hsp60 regulation of tumor cell apoptosis. J. Bio. Chem. 2008, v. 283, p. 5188-5194.
13. Kang B.H., Altieri D.C. Regulation of survivin stability by the aryl hydrocarbon receptor-interacting protein. J. Biol. Chem. 2006, v. 281, p. 24721-24727.
14. Sun C., Nettesheim D., Liu Z., Olejniczak E.T. Solution structure of human survivin and its binding interface with Smac/Diablo. Biochemistry. 2005, v. 44, p. 11-17.
15. Mera S., Magnusson M., Tarkowski A., Bokarewa M. Extracellular survivin up-regulates adhesion molecules on the surface of leukocytes changing their reactivity pattern. Journal of Leukocyte Biology. 2008, v. 83, p. 149-155.
16. Altieri D.C. Survivin, versatile-modulation of cell division and apoptosis in cancer. Oncogene. 2003, v. 22, p. 8581-8589.
17. Vong Q.P., Cao K., Li H.Y et al. Chromosome alignment and segregation regulated by ubiquitination of survivin. Science. 2005, v. 310, p. 1499-1504.
18. Clark S.J., Melki J. DNA methylation and gene silencing in cancer: Which is the guilty party? Oncogene. 2002, v. 21, p. 5380-5387.
19. Siddiquee K., Zhang S., Guida W.C. et al. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc. Natl. Acad. Sci. USA. 2007, v. 104, p. 7391-7396.
20. Kawakami H., Tomita M., Matsuda T. et al. Transcriptional activation of survivin through the NFkappaB pathway by human T-cell leukemia virus type I tax. Int. J. Cancer. 2005.
21. Lee C.W., Raskett С.М., Prudovsky I., Altieri D.C. (2008) Molecular dependence of estrogen receptor-negative breast cancer on a notch-survivin signaling axis. Cancer. Research. 2008, v. 68, p. 5273-5281.
22. Kim P.J., Plescia J., Clevers H. et al. Survivin and molecular pathogenesisof colorectal cancer. Lancet. 2003, v. 362, p. 205-209.
23. Cosgrave N., Hill A.D., Young L.S. Growth factor-dependent regulation of survivin by c-myc in human breast cancer. J. Mol. Endocrinol. 2006, v. 37, p. 377-390.
24. Mirza A., McGuirk M., Hockenberry T.N. et al. Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene. 2002, v. 21 (17), p. 2613-2622.
25. Jiang Y., Saavedra H.I., Holloway M.P. et al. (2004) Aberrant regulation of survivin by the RB/E2F family of proteins. J. Biol. Chem. 2004, v. 279, p. 40511-40520.
26. Zhang T., Otevrel T., Gao Z. et al. Evidence that APC regulates survivin expression: a possible mechanism contributing to the stem cell origin of colon cancer. Cancer. Research. 2001, v. 61, p. 8664-8667.
27. Semba S., Trapasso F., Fabbri M. et al. Fhit modulation of the Akt-survivin pathway in lung cancer cells: Fhit-tyrosine 114 (Y114) is essential. Oncogene. 2006, v. 25, p. 2860-2872.
28. Wang R.H., Zheng Y., Kim H.S. etal. (2008) Interplay among BRCA1, SIRT1 and Survivin during BRCAl-associated tumorigenesis. Mol. Cell. 2008, v. 32, p. 11-20.
29. Jin Q., Menter G.D., Mao L. et al. (2008) Survivin expression in normal human bronchial epithelial cells: an early and critical step in tumorigenesis induced by tobacco exposure. Carcinogenesis. 2008, v. 29 (8), p. 1614-1622.
30. Vaira V., Lee C.W., Goel H.L. et al. (2006) Regulation of survivin expression by IGF-1/mTOR signaling. Oncogene. 2006, v. 26 (19), p. 2678-2684.
31. Dasgupta P., Kinkade R., Joshi B. et al. (2006) Nicotine inhibits apoptosis induced by chemotherapeutic drugs by up-regulating XIAP and survivin. PNAS. 2006, v. 103 (16), p. 6332-6337.
32. Adida C., Berrebi D., Peuchmaur M. et al. (1998) Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. Lancet. 1998, v. 351, p. 882-883.
33. Lens S.M., Wolthuis R.M., Klompmaker R. et al. (2003) Survivin is required for a sustained spindle checkpoint arrest in response to lack of tension. EMBO J. 2003, v. 22, p.2934-2947.
34. Cheung P., Allis C.D., Sassone-Corsi P. Signalingto chromatin through histone modifications. Cell. 2000, v. 13, p. 263-271.
35. Sasai K., Katayama H., Stenoien D.L. et al. Aurora-C kinase is a noval cromossomal passenger protein that can complement Aurora-В kinase function in mitotic cells. Cell. Motil. Cytoskeleton. 2004, v. 59 (4), p. 249-263.
36. Lens S.M., Rodriguez J.A, Vader G. et al. Uncoupling the central spindle-associated function of the chromosomal passenger complex from its role at centromeres. Mol. Biol. Cell. 2006, v. 17, p. 1897-1909.
37. Delacour-Larose M., Thi M.N., Dimitrov S., Molla A. Role of survivin phosphorylation by aurora В in mitosis. Cell. Cycle. 2007, v. 6 (15), p. 1878-1885.
38. John C., Reed J.C. The Survivin saga goes in vivo. J. Clin. Invest. 2001, v. 108, p. 965-969.
39. Mareel M., Leroy A. Clinical, cellular, and molecular aspects of cancer invasion. Physiol. Rev. 2003, v. 83 (2), p. 337-376.
40. Altieri D.C. Validating survivin as a cancer therapeutic target. Nat. Rev. Cancer. 2003, v. 3 (1), p. 46-54.
41. Grossman D., Kim P.J., Blanc-Brude O. et al. Transgenic expression of survivin in keratinocytes counteracts UVB-induced apoptosis and cooperates with loss of p53. J. Clin. Invest. 2001, v. 108, p. 991-999.
42. Olie R.A., Simoes-Wust A.P., Baumann B. et al. A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Research. 2000, v. 60, p. 2085-2809.
43. Tamm I., Wang Y., Sausville E. et al. LAP-family protein surviving inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases and anticancer drugs. Cancer Research. 1998, v. 58, p. 5315-5320
44. Shin B.C., Sung B.J., Kim H. et al. An antiapoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry. 2001, v. 40, p. 1117-1123.
45. Banks D.P., Plescia J., Altieri D.C. Survivin does not inhibit caspase-3 activity. Blood. 2000, v. 96, p. 4002.
46. Chantalat L., Skoufias D.A., Kleman L.P. et al. Crystal structure of human survivin reveals a bow tie-shaped dimer with 2 unusual alpha-helical extensions. Mol. Cell. 2000, v. 6, p. 183-189.
47. Marusawa H., Matsuzawa S., Welsh K. et al. HBXIP functions as a cofactor of surviving in apoptosis suppression. EMBO J. 2003, v. 22, p. 2729-2740.
48. Dohi T., Okada К., Xia F. et al. An IAP-IAP complex inhibits apoptosis. J. Biol. Chem. 2004, v. 279, p. 34087-34090.
49. Du C., Fang M., Li Y. et al. Smac a mitochondrial protein that promotes cytochrome C-dependent caspase activationby eliminating LAP inhibition. Cell. 2000, v. 102, p. 33-42.
50. Liu Т., Brouha В., Grossman D. Rapid induction of mitochondrial events and caspase-independent apoptosis in Survivin-targeted melanoma cells. Oncogene. 2004, v. 23 (1), p. 39-48.
51. Sekimura A., Konishi A., Mizuno K. et al. Expression of Smac/DLABLO is a novel prognostic marker in lung cancer. Oncology Reports. 2004, v. 11, p. 797-802.
52. Baran M., Mollers L.N., Andersson S. et al. Survivin is an essential mediator of arthritis interacting with urokinase signalling. J. Cell Mol. Med. 2009, v. 13 (9B), p. 3797-3808.
53. Mehrotra S., Languino L.R., Raskett M.C. et al. IAP Regulation of Metastasis. Cancer. Cell. 2010, v. 17, p. 53-64.
54. Srinivasula S.M., Ashwell J.D. IAPs: what's in a name? Mol. Cell. 2008, v. 30, p. 123-135.
55. Parsons J.T., Slack-Davis J., Tilghman R., Roberts W.G. Focal adhesion kinase: targeting adhesion signaling pathways for therapeutic intervention. Clin. Cancer Res. 2008, v. 14, p. 627-632.
56. Monzo M., Rosell R., Felip E. et al. Anovelanti- apoptosis gene: reexpression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J. Clin. Oncol. 1999, v. 17, p. 2100-2104.
57. Tanaka K., Iwamoto S., Gon G. et al. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin. Cancer. Res. 2000, v. 6, p. 127-134.
58. Satoh К., Kaneko К., Hirota M. et al. Tumor necrosis factor-related apoptosis-inducing ligand and its receptor expression and the pathway of apoptosis in human pancreatic cancer. Pancreas. 2001, v. 23, p. 251-258.
59. Kappler M., Bache M., Bartel F. et al. Knockdown of survivin expression by small interfering RNA reduces the clonogenic survival of human sarcoma cell lines independently of p53. Cancer Gene Ther. 2004, v. 11, p. 186-193.
60. Chakravarti A., Noll E., Black P.M. et al. Quantitatively determined survivin expression levels are of prognostic value in human gliomas. J. Clin. Oncol. 2002, v. 20, p. 1063-1068.
61. Grossman D., McNiff J.M., Li F., Altieri D.C. Expression and targeting of the apoptosis inhibitor, survivin, in humanmelanoma. J. Invest. Dermatol. 1999, v. 113, p. 1076-1081.
62. Marioni G., Bertolin A., Giacomelli L. et al. Expression of the apoptosis inhibitor protein survivin in primary laryngeal carcinoma and cervical lymph node metastasis. Anticancer. Res. 2006, v. 26, p. 3813-3817.
63. Osaka E., Suzuki T., Osaka S. et al. Survivin as a prognostic factor for osteosarcoma patients. Acta Histochem. Cytochem. 2006, v. 39, p. 95-100.
64. Hinnis A.R., Luckett J.C., Walker R.A. Survivin is an independent predictor of short-term survival in poor prognostic breast cancer patients. Br. J. Cancer. 2007, v. 96, p. 639-645.
65. Nakagawa Y., Abe S., Kurata M. et al. LAP family protein expression correlates with poor outcome of multiple myeloma patients in association with chemotherapy-induced overex-pression of multidrug resistance genes. Am. J. Hematol. 2006, v. 81, p. 824-831.
66. Nakano J., Huang C., Liu D., Masuya D. et al. The clinical significance of splice variants and subcellular localization of survivin in nonsmall cell lung cancers. Br. J. Cancer. 2008, v. 98 (6), p. 1109-1117.
67. Книжник А.В., Ковалева О.В., Лактионов К.К. и соавт. Сравнительный анализ экспрессии белков Arf6, RalA и BIRC5 при НМРЛ. Молекулярная биология. 2011, 45 (2), с. 307-315.
68. Suga К., Yamamoto Т., Yamada Y. et al. Correlation between transcriptional expression of survivin isoforms and clinic-pathological findings in human colorectal carcinomas. Oncol. Rep. 2005, v. 13 (5), p. 891-897.
69. Ling X., Yang J., Tan D. et al. Differential expression of survivin-2B and survivin-DeltaEx3 is inversely associated with disease relapse and patient survival in nonsmallcell lung cancer (NSCLC). Lung Cancer. 2005, v. 49, p. 353-361.
70. Nouraee N., Mowla S.J., Ozhand A. et al. Expression of survivin and its spliced variants in bladder tumors as a potential prognostic marker. Urol. J. 2009, v. 6 (2), p. 101-108.
71. Youssef N.S., Hewedi I.H., Abd Raboh N.M. Immunohistochemical expression of survivin in breast carcinoma: relationship with clinic-pathological parameters, proliferation and molecular classification. J. Egypt Natl. Cane. Inst. 2008, v. 20 (4), p. 348-357.
72. Stauber R.H., Wolf Mann., Knauer K.S. Nuclear and Cytoplasmic Survivin: Molecular Mechanism, Prognostic, and Therapeutic Potential. Cancer Research. 2007, v. 67 (13), p. 5999-6002.
73. Vischioni В., van der Valk P., Span S. et al. 2004 Nuclear localization of survivin is a positive prognostic factor for survival in advanced nonsmallcell lung cancer. Annals of Oncology. V. 15 (11), p. 1654-1660.
74. Qi G., Tuncel H., Aoki E., Tanaka S. et al. Intracellular localization of survivin determines biological behavior in colorectal cancer. Oncol. Rep. 2009, v. 22 (3), p. 557-562.
75. Saito T., Arifm M.T., Hama S., Kajiwara Y. et al. Survivin subcellular localization in high-grade astrocytomas: simultaneous expression inboth nucleus and cytoplasm is negative prognostic marker. J. Neurooncol. 2007, v. 82 (2), p. 193-198.
76. Kappler M., Kohler T., Kampf C. et al. Increased survivin transcript levels: an independent negative predictor of survival in soft tissue sarcoma patients. Int. J. Cancer. 2001, v. 95, p. 360-363.
77. Kappler M., Kotzsch M., Bartel F. et al. Elevated expression level of survivin protein in soft-tissue sarcomas is a strong independent predictor of survival. Clin. Cancer Res. 2003, v. 9, p. 1098-1104.
78. Taubert H., Heidenreich C., Holzhausen H.J. et al. Expression of survivin detected by immunohistochemistry in the cytoplasm and in the nucleus is associated with prognosis of leiomyosarcoma and synovial sarcoma patients. BMC Cancer. 2010, v. 10, p. 65.
79. Taubert H., Kappler M., Bache M. et al. Elevated expression of survivinsplice variants predicts a poor outcome for soft tissue sarcomas patients. Oncogene. 2005, v. 24, p. 5258-5261.
80. Kappler M., Taubert H., Bartel F. et al. Radiosensitization, after a combined treatment of survivin siRNA and irradiation, is correlated with the activation of caspases 3 and 7 in a wt-p53 sarcoma cell line, but not in a mt-p53 sarcoma cell line. Oncol. Rep. 2005, v. 13, p. 167-172.
81. Endoh Т., Tsuji N., Asanuma K. et al. Survivin enhances telomerase activity via up-regulation of specificity protein 1- and c-Myc-mediated human telomerase reverse transcriptase gene transcription. 2005.
82. Wurl P., Kappler M., Meye A. et al. Coexpression of survivin and TERT and risk of tumour-related death in patients with soft tissue sarcoma. Lancet. 2002, v. 359, p. 943-945.
83. Osaka E., Suzuki T., Osaka S. et al. Survivin expression levels as independent predictors of survival for osteosarcoma patients. J. Orthop. Res. 2007, v. 25, p. 116-121.
84. Trieb K., Lehner R., Stulnig T. et al. Survivin expression in human osteosarcoma is a marker for survival. Eur. J. Surg. Oncol. 2003, v. 29, p. 379-382.
85. Wang W., Luo H., Wang A. Expression of survivin and correlation with PCNA in osteosarcoma. J. Surg. Oncol. 2006, v. 93, p. 578-584.
86. Do S.I., Jung W.W., Kim H.S., Park Y.К. The expression of epidermal growth factor receptor and its downstream signaling molecules in osteosarcoma. Int. J. Oncol. 2009, v. 34, p. 797-803.
87. Zucchini C., Rocchi A., Manara M.C. et al. Apoptotic genes as potential markers of metastatic phenotype in human osteosarcoma cell lines. Int. J. Oncol. 2008, v. 32, p. 17-31.
88. Zou J., Gan M., Mao N. et al. Sensitization of osteosarcoma cell line SaOS-2 to chemotherapy by downregulating survivin. Arch. Med. Res. 2010, v. 41, p. 162-169.
89. Wu Y.F., Liang X.J., Liu Y.Y. et al. Antisense oligonucleotide targeting survivin inhibits growth by inducing apoptosis in human osteosarcoma cells MG-63. Neoplasma. 2010, v. 57, p. 501-506.
90. Lechler R., Renkawitz T., Campean V. et al. The antiapoptotic gene survivin is highly expressed in human chondrosarcoma and promotes drug resistance in chondrosarcoma cells in vitro. BMC Cancer. 2011, v. 11, p. 120.
91. Zhang H. Survivin protein in UVB induced apoptosis of melanoma cells and in melanoma progression. Oncol. Rep. 2005, v. 13,p. 1121-1126.
92. Ding Y., Prieto V.G., Zhang P.S. et al. Nuclear expression of the anti-apoptotic protein survivin in malignant melanoma. Cancer. 2006, v. 106, p. 1123-1129.
93. Chen N., Gong J., Chen X. et al. Caspases and inhibitor of apoptosis proteins in cutaneous and mucosal melanoma: expression profile and clinic-pathologic significance. Hum. Pathol. 2009, v. 40, p. 950-956.
94. Piras F., Perra M.T., Murtas D. et al. Combinations of apoptosis and cell-cycle control biomarkers predict the outcome of human melanoma. Oncol. Rep. 2008, v. 20, p. 271-277.
95. Ryu B., Kim D.S., Deluca A.M., Alani R.M. Comprehensive expression profiling of tumor cell lines identifies molecular signatures of melanoma progression. PLoS One. 2007, v. 2, p. 594.
96. McKenzie J.A., Liu T., Goodson A.G., Grossman D. Survivin enhances motility of melanoma cells by supporting Akt activation and {alpha}5 integrin upregulation. Cancer. Res. 2010, v. 70, p. 7927-7937.
97. Grossman D., Kim P.L., Scheduler J.S., Altieri D.C. Inhibition of melanoma tumor growth in vivo by survivin targeting. Proc. Natl. Acad. Sci. USA 98. 2001, v. 98, p. 635-640.
98. Yan H., Thomas J., Liu T. et al. Induction of melanoma cell apoptosis and inhibition of tumor growth using a cell-permeable Survivin antagonist. Oncogene. 2006, v. 25, p. 6968-6974.
99. Tolcher A.W, Antonia S., Lewis L.D. et al. ASCO Annual Meeting. 2006, p. 3014.
100. Guha M., Altieri D.C. Survivin as a global target of intrinsic tumor suppression networks. Cell Cycle. 2009, v. 8 (17), p. 2708-2710.
Рецензия
Для цитирования:
Ковалева О.В., Шнейдерман А.Н., Чевкина Е.М., , , Сурвивин и его роль в патогенезе злокачественных опухолей. Саркомы костей, мягких тканей и опухоли кожи. 2011;(4):62-72.
For citation:
, , , Kovaleva O.V., Shneyderman A.N., Tchevkina E.M. SIRVIVIN AND ITS ROLE IN MALIGNANT TUMORS. Bone and soft tissue sarcomas, tumors of the skin. 2011;(4):62-72. (In Russ.)
Просмотров:
104
Послать статью по эл. почте 
